As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research.

* For an explanation of our use of non-GAAP financial measures refer to the "Note Regarding Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each ...

针对肺癌，公司预计将于 2025 年上半年对 tarlatamab（AMG757，DLL3xCD3双特异性 T 细胞接合器）用于二线治疗小细胞肺癌的三期临床试验进行数据读出 ...

Honouring the Treaty relationship is a fundamental part of advancing reconciliation in Canada and rebuilding trust with First Nation communities. Today, Chief Wilfred King of Kiashke Zaaging ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive ...

BRUKINSA ® (zanubrutinib) is an orally available, small molecule inhibitor of BTK designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and ...

Dr. Daniel Leonard (Medicine): A 65-year-old woman was transferred to this hospital for evaluation of pancytopenia and back pain. The patient had been in her usual state of health until 3 weeks ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell ...